Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Haematologica
.
2021 Aug 19.
doi: 10.3324/haematol.2021.279802.
Online ahead of print.
Authors
Johannes Duell
1
,
Kami J. Maddocks
2
,
Eva González-Barca
3
,
Wojciech Jurczak
4
,
Anna Marina Liberati
5
,
Sven De Vos
6
,
Zsolt Nagy
7
,
Aleš Obr
8
,
Gianluca Gaidano
9
,
Pau Abrisqueta
10
,
Nagesh Kalakonda
11
,
Marc André
12
,
Martin Dreyling
13
,
Tobias Menne
14
,
Olivier Tournilhac
15
,
Marinela Augustin
16
,
Andreas Rosenwald
17
,
Maren Dirnberger-Hertweck
18
,
Johannes Weirather
18
,
Sumeet Ambarkhane
18
,
Gilles Salles
19
Affiliations
1
Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg.
2
Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH.
3
Department of Hematology, Institut Catalá d'Oncologia (ICO), Hospital Duran i Reynals, Universitat de Barcelona, Barcelona.
4
Maria Sklodowska-Curie National Research Institute of Oncology, Kraków.
5
Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni.
6
Department of Medicine, Ronald Reagan UCLA Medical Center, Santa Monica, CA.
7
1st Department of Internal Medicine, Semmelweis University, Budapest.
8
Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic.
9
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara.
10
Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona.
11
Molecular and Clinical Cancer Medicine, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool.
12
Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir.
13
Department of Medicine III, LMU University Hospital, Munich.
14
Department of Haematology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne.
15
Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, Clermont-Ferrand.
16
Department of Hematology and Oncology, Paracelcus Medical University, Klinikum Nürnberg, Nürnberg.
17
Institute of Pathology, University of Würzburg, Würzburg.
18
MorphoSys AG, Planegg.
19
Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon.
PMID:
34407608
DOI:
10.3324/haematol.2021.279802
Abstract
Not available.